share_log

Universe Pharmaceuticals | 6-K: Report of foreign private issuer (related to financial reporting)

Universe Pharmaceuticals | 6-K: Report of foreign private issuer (related to financial reporting)

大自然药业 | 6-K:外国发行人报告(业绩相关)
美股SEC公告 ·  2024/10/10 16:15

Moomoo AI 已提取核心信息

Universe Pharmaceuticals announced the appointment of Enrome LLP as its new independent registered public accounting firm effective October 8, 2024, replacing YCM CPA INC. The change was approved by the company's audit committee after careful consideration and evaluation.The company emphasized that the auditor change was not due to any disagreements on accounting principles, financial statement disclosure, or auditing procedures. YCM's audit reports for fiscal years 2022 and 2023 contained no adverse opinions or modifications. The only notable issue was previously reported material weaknesses under Item 15 of the company's annual report for fiscal year 2023.Prior to Enrome's engagement, there were no consultations regarding specific transactions, audit opinions, or financial reporting matters between the firm and Universe Pharmaceuticals. The company has provided YCM with the disclosure and requested their confirmation letter to the SEC.
Universe Pharmaceuticals announced the appointment of Enrome LLP as its new independent registered public accounting firm effective October 8, 2024, replacing YCM CPA INC. The change was approved by the company's audit committee after careful consideration and evaluation.The company emphasized that the auditor change was not due to any disagreements on accounting principles, financial statement disclosure, or auditing procedures. YCM's audit reports for fiscal years 2022 and 2023 contained no adverse opinions or modifications. The only notable issue was previously reported material weaknesses under Item 15 of the company's annual report for fiscal year 2023.Prior to Enrome's engagement, there were no consultations regarding specific transactions, audit opinions, or financial reporting matters between the firm and Universe Pharmaceuticals. The company has provided YCM with the disclosure and requested their confirmation letter to the SEC.
大自然药业宣布任命Enrome LLP为其新的独立注册公共会计师事务所,自2024年10月8日起生效,取代YCm CPA INC。该变更经过公司审计委员会的仔细考虑和评估后获得批准。公司强调,审计师的更换并非由于会计原则、财务报表披露或审计程序上的任何分歧。YCM针对2022和2023财年的审计报告没有不利意见或修改。唯一值得注意的问题是,在公司的2023财年年报第15项下曾报告过的重大缺陷。在Enrome被聘用之前,事务所和大自然药业之间没有关于特定交易、审计意见或财务报告事宜的咨询。公司已向YCm提供了披露,并请求其向美国证券交易委员会确认的函件。
大自然药业宣布任命Enrome LLP为其新的独立注册公共会计师事务所,自2024年10月8日起生效,取代YCm CPA INC。该变更经过公司审计委员会的仔细考虑和评估后获得批准。公司强调,审计师的更换并非由于会计原则、财务报表披露或审计程序上的任何分歧。YCM针对2022和2023财年的审计报告没有不利意见或修改。唯一值得注意的问题是,在公司的2023财年年报第15项下曾报告过的重大缺陷。在Enrome被聘用之前,事务所和大自然药业之间没有关于特定交易、审计意见或财务报告事宜的咨询。公司已向YCm提供了披露,并请求其向美国证券交易委员会确认的函件。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息